Cipla's Q4 FY 2025-26 Quarterly Results

Result Summary

• Cipla Ltd reported a 8.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 4.7%.
• Its expenses for the quarter were down by 2.8% QoQ and up 7.7% YoY.
• The net profit decreased 19.5% QoQ and decreased 55.3% YoY.
• The earnings per share (EPS) of Cipla Ltd stood at 6.86 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Cipla Ltd is a leading pharmaceutical company in India known for its wide portfolio of healthcare products. Established in 1935, Cipla has grown to become a major player in the pharmaceutical industry, manufacturing a range of products including generic medicines, active pharmaceutical ingredients, and a variety of healthcare products. The company is recognized for its efforts in making medications accessible and affordable across various therapeutic categories such as respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS. Cipla operates in over 80 countries, providing high-quality and affordable medicines to patients worldwide. The company continues to invest in research and development to innovate and expand its product offerings. As of the date of this report, there is no specific information available on recent major developments within the company.

Revenue

In the fourth quarter of the fiscal year 2026, Cipla Ltd reported a total income of ₹6689.36 crores. This represents a decline of 8.1% compared to the previous quarter (Q3FY26), where the total income was ₹7280.82 crores. Comparing year-over-year, the revenue decreased by 4.7% from ₹7019.15 crores in Q4FY25. The decline in revenue on both a quarterly and annual basis is noteworthy. Such variations in total income could be attributed to a variety of factors, including changes in market demand, pricing strategies, or macroeconomic conditions affecting the pharmaceutical sector. The financial data provided does not specify the exact reasons for the revenue changes.

Profitability

Cipla Ltd's profitability experienced a significant change in Q4FY26. The profit before tax (PBT) for this period was ₹707.06 crores, marking a decrease of 20.8% from the previous quarter's PBT of ₹893.11 crores. On a year-over-year basis, the PBT witnessed a substantial decline of 53.0% from ₹1504.30 crores in Q4FY25. The tax expense for Q4FY26 was ₹156.95 crores, reflecting a decrease of 28.2% from the previous quarter and a 43.8% reduction year-over-year. Consequently, the profit after tax (PAT) stood at ₹542.51 crores, which is 19.5% lower than the previous quarter and 55.3% less compared to the same quarter last year. Earnings per share (EPS) for Q4FY26 was ₹6.86, showing a decrease of 17.9% QoQ and 54.6% YoY. These figures highlight significant changes in the company's profitability metrics over the periods considered.

Operating Metrics

The operating expenses for Cipla Ltd in Q4FY26 were ₹5940.28 crores, which indicates a decrease of 2.8% from the previous quarter's total expenses of ₹6111.80 crores. However, on a year-over-year basis, the expenses increased by 7.7% from ₹5514.85 crores in Q4FY25. The reduction in expenses on a quarterly basis, juxtaposed with an annual increase, provides insight into the company's cost management strategies and operational efficiency over different time frames. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio were not provided in the data, limiting the analysis of the company's financial health in these specific areas. The financial metrics indicate varying trends in the company's operational performance over the analyzed periods.